Gilead Sciences (NASDAQ:GILD)

GettyImages_183162370

Large Companies With Fastest Revenue and Earnings Growth in 2015

This year is nearing the halfway mark and analysts are beginning to project their biggest winners and losers on the year. S&P Capital IQ recently released a report regarding the ...
Read Full Story »
biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
investor research

10 Companies to Own for the Next Decade

The decade from 2010 to 2020 has come with far less turbulence so far than the prior decade. Many investors might have grown to think all over again that they can ...
Read Full Story »
buy sell

Key Dalio and Bridgewater Position Changes: Alcoa, Apple, CenturyLink, Cisco, Gilead, Emerging Markets

Bridgewater Associates is one of the most widely followed and most renowned hedge funds in the world. After all, it is also one of the financial giants, and it is ...
Read Full Story »
biotech

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
gilead

Gilead Avoids the Earnings Hangman

Gilead Sciences Inc. (NASDAQ: GILD) reported its first-quarter results Thursday after the markets closed. The biotech giant had $2.94 in earnings per share (EPS) on $7.59 billion in revenue, versus ...
Read Full Story »
Biotechnology word cloud

What to Expect From Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) will report its first-quarter earnings Thursday after the markets close. Thomson Reuters has consensus estimates of $2.32 in earnings per share (EPS) on $6.92 billion ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Hepatitis Virus

Opposing Views on Gilead Hepatitis C Presentation

Abstracts from the upcoming European Association for the Study of the Liver (EASL) conference have been published and analysts are doing their best to make sense of them. Gilead Sciences ...
Read Full Story »
payoff

5 Stocks to Buy for Big Revenue Growth

With the stock market trading at one of the highest multiples in years, investors looking to stay long stocks need to find companies that are showing significant top line growth. ...
Read Full Story »
research

Major Biotech Is So-So for Short Sellers

The short interest data are out for the March 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
investor research

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

There are two events in the biotech world that can quickly bring down the price of a stock. One is to have a failed or, sometimes worse, a misunderstood clinical ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Chesapeake, eBay, Enterprise, Gilead, Newmont, Wynn and More

Stocks were indicated marginally lower on Thursday after a post-FOMC rally on Wednesday. The one trend that keeps holding true is that investors buy stocks after every sell-off, something that ...
Read Full Story »
Euro

How the Weaker Euro Is Impacting Biotech Earnings

It is no secret that a strong dollar and a weak euro, and foreign currency environment, are acting to hurt U.S. corporate earnings. Many investors might think that biotech earnings ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get More Aggressive on Big Biotech

The short interest data are out for the February 27 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »